Synthetic cannabinoids Receptor Agonist (SCRA) intoxication presents with various medical and psychiatric symptoms. The products are sold as K2 or Spice. The symptoms range from agitation, altered mental status (AMS), lethargy, paranoid behavior, psychosis and seizures. In some cases, brief psychiatric or inpatient medicine admission was required for stabilization. Some patients seem to stay longer for observation in the ED. These patients worsen the already problematic ED crowding. To assess K2-related ED presentation, length of stay in the ED and types of disposition over a 5 year period. A retrospective chart review of patients who presented with K2 intoxication. Charts were reviewed from January 1, 2012 until December 31st, 2016 excluding 2016. Demographics, age, gender, past psychiatric illness and other substance abuse history were reviewed. A total of 1405 patients were seen for K2-related ED visits from January 1, 2012 until December 31st, 2016 of which 1279 patients (91%) were male and 126 patients (9%) were female. One hundred thirty nine patients (9.9%) were hospitalized and 1266 patients (90.1%) were either discharged or left from the ED. Twenty-eight (2.0%) stayed more than 16 hours in the ED. Of the 53 patients, whose urine the showed benzodiazepine or opiates 36 patients stayed more than 6 hours in the ED. Most patients with K2 use were male (91%) between the ages of 19 and 50 years (76.4%). There was a surge in K2-related presentation in 2015, particularly in the months of April until November. In addition, K2-related intoxication led to prolonged ED stay, which could affect the ED crowding phenomenon. A concerted effort from public pressure and legislative measures led to a reduction of K2-related visits to the ED.
| Published in | American Journal of Internal Medicine (Volume 8, Issue 1) |
| DOI | 10.11648/j.ajim.20200801.16 |
| Page(s) | 30-33 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
SCRAs, Intoxication, ED Crowding, Length of Stay
| [1] | Alipour, A., et al., Review of the many faces of synthetic cannabinoid toxicities. Ment Health Clin, 2019. 9 (2): p. 93-99. |
| [2] | Argamany, J. R., K. R. Reveles, and B. Duhon, Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am J Emerg Med, 2016. 34 (4): p. 765 e1-2. |
| [3] | Bernson-Leung, M. E., L. Y. Leung, and S. Kumar, Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis, 2014. 23 (5): p. 1239-41. |
| [4] | Buser, G. L., et al., Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol (Phila), 2014. 52 (7): p. 664-73. |
| [5] | Castaneto, M. S., et al., Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend, 2014. 144: p. 12-41. |
| [6] | Lapoint, J., et al., Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila), 2011. 49 (8): p. 760-4. |
| [7] | Mir, A., et al., Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics, 2011. 128 (6): p. e1622-7. |
| [8] | Schneir, A. B. and T. Baumbacher, Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol, 2012. 8 (1): p. 62-4. |
| [9] | Tai, S. and W. E. Fantegrossi, Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr Addict Rep, 2014. 1 (2): p. 129-136. |
| [10] | van Amsterdam, J., T. Brunt, and W. van den Brink, The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol, 2015. 29 (3): p. 254-63. |
| [11] | Waugh, J., et al., Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. Clin Toxicol (Phila), 2016. 54 (6): p. 512-8. |
| [12] | Hassen, G. W., et al., Analysis of K2 products sold as incense. Am J Emerg Med, 2018. 36 (7): p. 1307-1309. |
| [13] | Hassen, G. W., et al., K2 types and their contents: are product disclosures true? Am J Emerg Med, 2015. 33 (6): p. 845-6. |
| [14] | Hassen, G. W. and H. Kalantari, Synthetic drugs: time to ring the warning bell? Am J Emerg Med, 2013. 31 (12): p. 1714-5. |
| [15] | Reyes, H. A., et al., Effect of Synthetic Cannabinoids in Older Adults. J Am Geriatr Soc, 2017. 65 (9): p. 2115-2117. |
| [16] | Roy, A. A., et al., The rise in K2 use with varying clinical symptoms and the potential for ED crowding. Am J Emerg Med, 2015. 33 (4): p. 582. |
| [17] | Sweeney, B., et al., Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med, 2016. 34 (1): p. 121 e1-2. |
| [18] | Von Der Haar, J., et al., Synthetic Cannabinoids and Their Effects on the Cardiovascular System. J Emerg Med, 2016. 50 (2): p. 258-62. |
| [19] | https://www.nytimes.com/2016/07/15/nyregion/k2-overdose-spike-in-new-york-at-least-130-cases-this-week-alone.html. |
| [20] | https://www.nytimes.com/2016/07/13/nyregion/k2-synthetic-marijuana-overdose-in-brooklyn.html?action=click&contentCollection=N.Y.%20%2F%. |
| [21] | https://consumer.healthday.com/public-health-information-30/poisons-health-news-537/synthetic-pot-laced-with-rat-poison-lands-people-in-the-er-749632.html. |
| [22] | Fantegrossi, W. E., et al., Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta (9) -THC: mechanism underlying greater toxicity? Life Sci, 2014. 97 (1): p. 45-54. |
| [23] | Basavarajappa, B. S. and S. Subbanna, Potential Mechanisms Underlying the Deleterious Effects of Synthetic Cannabinoids Found in Spice/K2 Products. Brain Sci, 2019. 9 (1). |
| [24] | Solimini, R., et al., Hepatotoxicity associated to synthetic cannabinoids use. Eur Rev Med Pharmacol Sci, 2017. 21 (1 Suppl): p. 1-6. |
| [25] | Varga, Z. V., et al., Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol, 2015. 309 (9): p. H1453-67. |
| [26] | Pines, J. M., Emergency department crowding in California: a silent killer? Ann Emerg Med, 2013. 61 (6): p. 612-4. |
| [27] | Hassen, G. W., F. Ghobadi, and H. Kalantari, Synthetic drugs: a new trend and the hidden danger. Am J Emerg Med, 2013. 31 (9): p. 1413-5. |
| [28] | https://www.nytimes.com/2016/07/14/nyregion/k2-overdoses-brooklyn-police-raids.html?_r=0. |
| [29] | http://nymag.com/intelligencer/2016/07/after-k2-overdose-raids-and-protests.html. |
APA Style
Getaw Worku Hassen, Andrew Eng, Ioana Scherbakova, Aida Eliza Abdul Majid, Alessandra Renee Piscina, et al. (2020). Synthetic Cannabinoid Receptor Agonist-related Intoxication: Impact and Legislative Success. American Journal of Internal Medicine, 8(1), 30-33. https://doi.org/10.11648/j.ajim.20200801.16
ACS Style
Getaw Worku Hassen; Andrew Eng; Ioana Scherbakova; Aida Eliza Abdul Majid; Alessandra Renee Piscina, et al. Synthetic Cannabinoid Receptor Agonist-related Intoxication: Impact and Legislative Success. Am. J. Intern. Med. 2020, 8(1), 30-33. doi: 10.11648/j.ajim.20200801.16
AMA Style
Getaw Worku Hassen, Andrew Eng, Ioana Scherbakova, Aida Eliza Abdul Majid, Alessandra Renee Piscina, et al. Synthetic Cannabinoid Receptor Agonist-related Intoxication: Impact and Legislative Success. Am J Intern Med. 2020;8(1):30-33. doi: 10.11648/j.ajim.20200801.16
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20200801.16,
author = {Getaw Worku Hassen and Andrew Eng and Ioana Scherbakova and Aida Eliza Abdul Majid and Alessandra Renee Piscina and Thara Amilineni and Cynthia Francois and Asha Roy and Kevin Yiu and Canny Li and Michael Lyashenko and Monica Diep and Roger Chirurgi and Golnar Pashmforoosh and Hossein Kalantari},
title = {Synthetic Cannabinoid Receptor Agonist-related Intoxication: Impact and Legislative Success},
journal = {American Journal of Internal Medicine},
volume = {8},
number = {1},
pages = {30-33},
doi = {10.11648/j.ajim.20200801.16},
url = {https://doi.org/10.11648/j.ajim.20200801.16},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20200801.16},
abstract = {Synthetic cannabinoids Receptor Agonist (SCRA) intoxication presents with various medical and psychiatric symptoms. The products are sold as K2 or Spice. The symptoms range from agitation, altered mental status (AMS), lethargy, paranoid behavior, psychosis and seizures. In some cases, brief psychiatric or inpatient medicine admission was required for stabilization. Some patients seem to stay longer for observation in the ED. These patients worsen the already problematic ED crowding. To assess K2-related ED presentation, length of stay in the ED and types of disposition over a 5 year period. A retrospective chart review of patients who presented with K2 intoxication. Charts were reviewed from January 1, 2012 until December 31st, 2016 excluding 2016. Demographics, age, gender, past psychiatric illness and other substance abuse history were reviewed. A total of 1405 patients were seen for K2-related ED visits from January 1, 2012 until December 31st, 2016 of which 1279 patients (91%) were male and 126 patients (9%) were female. One hundred thirty nine patients (9.9%) were hospitalized and 1266 patients (90.1%) were either discharged or left from the ED. Twenty-eight (2.0%) stayed more than 16 hours in the ED. Of the 53 patients, whose urine the showed benzodiazepine or opiates 36 patients stayed more than 6 hours in the ED. Most patients with K2 use were male (91%) between the ages of 19 and 50 years (76.4%). There was a surge in K2-related presentation in 2015, particularly in the months of April until November. In addition, K2-related intoxication led to prolonged ED stay, which could affect the ED crowding phenomenon. A concerted effort from public pressure and legislative measures led to a reduction of K2-related visits to the ED.},
year = {2020}
}
TY - JOUR T1 - Synthetic Cannabinoid Receptor Agonist-related Intoxication: Impact and Legislative Success AU - Getaw Worku Hassen AU - Andrew Eng AU - Ioana Scherbakova AU - Aida Eliza Abdul Majid AU - Alessandra Renee Piscina AU - Thara Amilineni AU - Cynthia Francois AU - Asha Roy AU - Kevin Yiu AU - Canny Li AU - Michael Lyashenko AU - Monica Diep AU - Roger Chirurgi AU - Golnar Pashmforoosh AU - Hossein Kalantari Y1 - 2020/01/31 PY - 2020 N1 - https://doi.org/10.11648/j.ajim.20200801.16 DO - 10.11648/j.ajim.20200801.16 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 30 EP - 33 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20200801.16 AB - Synthetic cannabinoids Receptor Agonist (SCRA) intoxication presents with various medical and psychiatric symptoms. The products are sold as K2 or Spice. The symptoms range from agitation, altered mental status (AMS), lethargy, paranoid behavior, psychosis and seizures. In some cases, brief psychiatric or inpatient medicine admission was required for stabilization. Some patients seem to stay longer for observation in the ED. These patients worsen the already problematic ED crowding. To assess K2-related ED presentation, length of stay in the ED and types of disposition over a 5 year period. A retrospective chart review of patients who presented with K2 intoxication. Charts were reviewed from January 1, 2012 until December 31st, 2016 excluding 2016. Demographics, age, gender, past psychiatric illness and other substance abuse history were reviewed. A total of 1405 patients were seen for K2-related ED visits from January 1, 2012 until December 31st, 2016 of which 1279 patients (91%) were male and 126 patients (9%) were female. One hundred thirty nine patients (9.9%) were hospitalized and 1266 patients (90.1%) were either discharged or left from the ED. Twenty-eight (2.0%) stayed more than 16 hours in the ED. Of the 53 patients, whose urine the showed benzodiazepine or opiates 36 patients stayed more than 6 hours in the ED. Most patients with K2 use were male (91%) between the ages of 19 and 50 years (76.4%). There was a surge in K2-related presentation in 2015, particularly in the months of April until November. In addition, K2-related intoxication led to prolonged ED stay, which could affect the ED crowding phenomenon. A concerted effort from public pressure and legislative measures led to a reduction of K2-related visits to the ED. VL - 8 IS - 1 ER -
Information
Email: